C2C Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History

C2C Wealth Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,694	Closed	-$835K	–	218
2023 Q3	$835K	Buy	1,694 +5	+0.3%	+$2.66K	0.12%	92
2023 Q2	$889K	Sell	1,689 -45	-3%	-$24.3K	0.12%	90
2023 Q1	$1M	Buy	+1,734	New	+$977K	0.16%	80

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

C2C Wealth Management's TMO Position: Q4 2023 in Review

C2C Wealth Management sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 1,694 shares — an estimated $835K sold.

C2C Wealth Management first reported a position in TMO in Q1 2023 and held it in 3 quarters. The position peaked at $1M in Q1 2023. 2,488 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

C2C Wealth Management reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
C2C Wealth Management sold 1,694 Thermo Fisher Scientific shares in Q4 2023, an estimated $835K.
C2C Wealth Management first reported a position in Thermo Fisher Scientific in Q1 2023 and held it in 3 quarters.
C2C Wealth Management's Thermo Fisher Scientific position peaked at $1M in Q1 2023.
2,488 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on C2C Wealth Management's 13F filing for Q4 2023, filed 13 Feb 2024.